SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending due to its strategic pivot from Bitcoin mining to a high-performance computing and AI data center provider, backed by significant power infrastructure acquisitions and bullish institutional coverage. The community is actively discussing its high short interest and long-term growth potential as an AI infrastructure play, amidst varying views on short-term price action.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing a dramatic surge to new 52-week highs, driven by high call option activity and a substantial short interest, sparking widespread anticipation of an intensifying gamma and short squeeze. The community is actively discussing the company's momentum as a commercial-stage leader in cancer treatment, with many seeing potential for significant long-term wealth creation.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc. is experiencing high volatility following mixed earnings that reported strong subscriber growth but weak forward guidance and significant regulatory and litigation risks concerning its weight-loss segment. The community is fiercely divided, with many anticipating a massive short squeeze due to high short interest, while others remain cautious, highlighting the ongoing legal uncertainties.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending as investors anticipate its upcoming earnings report, widely expected to mark its 18th consecutive beat and raise, with many hoping for its first positive GAAP EPS. Despite a broader software sector sell-off fueled by AI fears, the community highlights Zeta's proprietary data moat, AI capabilities, and OpenAI partnership as key drivers for its undervalued position and potential for a significant short squeeze.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Vir Biotechnology is actively trending after announcing a major collaboration with Astellas Pharma for its prostate cancer immunotherapy asset, VIR-5500, which is supported by positive Phase 1 data and several analyst upgrades. The market is buzzing with discussions about the stock's short-squeeze potential, fueled by substantial partnership payments and its reportedly high short interest.

Rich Sparkle Holdings Ltd. engages in the provision of financial printing and corporate services. The firm offers typesetting, proofreading, translation, design, and printing of listing documents, financial reports, fund documents, circulars, and announcements. It also delivers advisory services, such as conducting internal control assessment and environmental, social and governance performance evaluation, and other services including provision of co-working space. The company was founded in 2016 and is headquartered in Hong Kong.

Rich Sparkle Holdings Ltd.

Rich Sparkle Holdings Limited

ANPA is trending following the completed acquisition of TikTok icon Khaby Lame's core company, driving intense speculation around its potential for explosive gains as a low-float Hong Kong stock, while a significant portion of the community warns of an unsustainable valuation and potential for a sharp decline.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending following a notable stock decline driven by market concerns that Anthropic's AI tool for COBOL modernization could disrupt its legacy mainframe business. However, a strong counter-narrative from analysts and the community suggests this is an overreaction, pointing to IBM's strategic partnership with Anthropic and its own robust AI solutions for enterprise modernization, positioning the dip as a potential buying opportunity.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and decor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is trending after its Q4 earnings saw an EPS beat offset by a sales miss and cautious forward guidance, sparking community debate about the impact of housing market weakness versus resilient professional customer demand, alongside a noted dividend increase.

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit is actively discussed following its partnership with Anthropic to embed AI into financial apps, a move the community views as either a significant moat expansion or an attempt to counter broader AI disruption fears weighing on the SaaS sector. This development intensifies speculation regarding its upcoming earnings and the stock's current deeply oversold valuation.

Keysight Technologies, Inc. engages in the provision of electronic design and test solutions that are used in the design, development, manufacture, installation, deployment, validation, optimization, and secure operation of electronics systems to communications, networking, and electronics industries. It operates through the Communications Solutions Group (CSG) and Electronic Industrial Solutions Group (EISG) segments. The CSG segment serves customers spanning the global commercial communications and aerospace, defense, and government end markets. The EISG segment offers test and measurement solutions across electronic industrial end markets, focusing on applications in the automotive, and energy industry and measurement solutions for semiconductor design and manufacturing, consumer electronics, education, and general electronics manufacturing. The company was founded by William R. Hewlett and David Packard in 1937 and is headquartered in Santa Rosa, CA.

Keysight Technologies Inc

Keysight Technologies is trending after a robust Q1 earnings beat and raised guidance, fueled by accelerating demand from AI data centers, aerospace, and defense sectors. The community is actively discussing the company's deeper-than-expected role in AI infrastructure testing and validation, attracting significant analyst upgrades and bullish sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CLNN - isn’t this kind of telling?

Regarding the Phase 3 trial:

“The trial design protocol has already been discussed with and reviewed by the FDA.”

Ryan Mulholland

mark

StockTwits for iOS

Clene Inc

 - isn’t this kind of telling?

Regarding the Phase 3 trial:

“The trial design protocol has already been discussed with and reviewed by the FDA.”

Exact Sciences Corp.

Generac Holdings Inc

Teladoc Health Inc

Pagaya Technologies Ltd

Klarna Group plc

Steve

@Woodman7 agreed. Rob said it recently in a video call. “Had phase 2 primary endpoint been survival, we would be having different conversations right now.” (Paraphrase)
Phase 3 will be based on overall survival. We know safety is fine. Phase 3 will lead to approval. Soooo…why make PALS wait?!
It just makes too much sense for accelerated approval.

 agreed. Rob said it recently in a video call. “Had phase 2 primary endpoint been survival, we would be having different conversations right now.” (Paraphrase)
Phase 3 will be based on overall survival. We know safety is fine. Phase 3 will lead to approval. Soooo…why make PALS wait?!
It just makes too much sense for accelerated approval.

Cabaletta Bio Inc

Acurx Pharmaceuticals Inc

NeuroSense Therapeutics Ltd

Amylyx Pharmaceuticals Inc

@Woodman7 They completed ALS P3 trial design in 2025 so now they have to start the trial as soon as the NDA filing is accepted. The full timeline for 2026 goes like: 
1. FDA Type-C Meeting in Q1 
2. NDA Filing in Q2 
3. PDUFA sometime in Q3  
4. Start dosing in ALS P3 Q3 onwards 
5. NDA acceptance end of 2026 / start of 2027 
7. Acc. Approval for ALS and selling 2027 onwards

StockTwits Web

 They completed ALS P3 trial design in 2025 so now they have to start the trial as soon as the NDA filing is accepted. The full timeline for 2026 goes like: 
1. FDA Type-C Meeting in Q1 
2. NDA Filing in Q2 
3. PDUFA sometime in Q3  
4. Start dosing in ALS P3 Q3 onwards 
5. NDA acceptance end of 2026 / start of 2027 
7. Acc. Approval for ALS and selling 2027 onwards

Chris150

@Chris150 - i’m not a biotech expert by any means, but when FDA is helping you plan out Phase 3, when phase 2 hasn’t been concluded kind of tells me what’s gonna happen re: the decisions on phase 2, no?

 - i’m not a biotech expert by any means, but when FDA is helping you plan out Phase 3, when phase 2 hasn’t been concluded kind of tells me what’s gonna happen re: the decisions on phase 2, no?

@Woodman7 I don&#39;t get you here. Phase 2 studies were RESCUE (in Australia) and HEALEY (Harvard platform), they have concluded and many ALS patients are on extended access protocol in HEALEY (EAP). RESTORE is the P3.

 I don't get you here. Phase 2 studies were RESCUE (in Australia) and HEALEY (Harvard platform), they have concluded and many ALS patients are on extended access protocol in HEALEY (EAP). RESTORE is the P3.

@Chris150 - right, I just meant that they still are waiting for the NDA from all the previous work

 - right, I just meant that they still are waiting for the NDA from all the previous work

@Woodman7 Data from RESCUE, HEALEY and HEALEY EAP were collected in order to support NfL biomarker reduction and file the NDA in Q2 2026. It is quite clear I think.

 Data from RESCUE, HEALEY and HEALEY EAP were collected in order to support NfL biomarker reduction and file the NDA in Q2 2026. It is quite clear I think.